May 16, 2012 Inovio Synthetic DNA Vaccine Achieves Proof of Principle With Robust Antibody and T Cell Responses Against Diverse H5N1 Influenza Strains
|
|
|
|
|
May 1, 2012 Cancer Vaccine in Phase II Clinical Study
|
Apr 2, 2012 Second DOD grant extends development and testing of novel surface electroporation delivery device for synthetic DNA vaccines
|
|
|
|
|
|
|
Mar 13, 2012 Significant T-cell responses against multiple HIV antigens demonstrate potential of Inovio's synthetic vaccines for HIV therapy
|
|
|
Mar 5, 2012 Inovio adds synthetic vaccines for diseases caused by HPV 6 and 11 to existing Type 16 and 18 vaccines; will continue to expand products against cancer-causing HPV
|
|
|
Feb 22, 2012 Electroporation delivery platform presents new avenue to enable development of targeted RNA-based therapies for untreatable diseases and conditions
|
Feb 21, 2012 Dr. David B. Weiner awarded AAAS distinction for his pioneering research of synthetic DNA vaccines
|
|
|
Jan 31, 2012 Cross-strain immune responses generated by Inovio's novel SynCon® vaccine design in additional subtypes build on prior positive data from H5N1 and H1N1 subtypes
|
|
|
|
|
|
|
|
|
|
|
|
|
Nov 17, 2011 World Health Organization Told Inovio's Vaccine Generates Four-Fold Increase in HAI Titers in 50% of Subjects Following Intradermal Boost
|
|
|
Oct 31, 2011 Fierce Vaccines Profiles Novel Synthetic Cancer Vaccine
|
| |
